Sales of Boehringer Ingelheim's diabetes, pulmonary drugs jump within $11B+ first-half total
Boehringer Ingelheim’s pharma division sales led company earnings for the first half of 2022, notching a sales increase of almost 12%. Its pharma business accounted for €8.4 billion of its overall €11.2 billion first-half sales, the pharma company reported on Wednesday.
Leading the way in pharma sales were the diabetes brand Jardiance at €2.5 billion and idiopathic pulmonary fibrosis drug Ofev at €1.5 billion in the first half. Jardiance’s sales jumped by more than 74% compared to the first half of 2021 sales of €1.4 billion. Full-year 2021 Jardiance sales were €3.9 billion, while Ofev earned €2.5 billion.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,200+ biopharma pros reading Endpoints daily — and it's free.